Skip to main content
. 2019 Feb 1;10(10):1031–1044. doi: 10.18632/oncotarget.26613

Figure 4.

Figure 4

Whole body near infrared imaging of the EGFR-positive murine xenograft model DLD-1-iRFP-702 following treatment with (A) Normal saline, (B) nimotuzumab (C) nimotuzumab-PEG6-DM1-Low, and (D) nimotuzumab-PEG6-DM1-High. Mice were treated with three doses (15 mg/kg) of nimotuzumab or nimotuzumab ADCs or with an equivalent volume of normal saline on day 0, 8 and 16. Representative near-infrared posterior whole-body images merged with white light images of CD-1 nude mice bearing subcutaneous DLD-1-iRFP-702 xenografts (right hind flank) are presented.